Aditxt (NASDAQ:ADTX – Get Free Report) and Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.
Risk & Volatility
Aditxt has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.
Earnings & Valuation
This table compares Aditxt and Sol-Gel Technologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $14,336.00 | 0.02 | -$41.71 million | ($100,788.35) | -0.00 |
| Sol-Gel Technologies | $19.39 million | 9.49 | -$6.13 million | ($5.64) | -9.97 |
Sol-Gel Technologies has higher revenue and earnings than Aditxt. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings for Aditxt and Sol-Gel Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
Sol-Gel Technologies has a consensus price target of $197.50, suggesting a potential upside of 251.11%. Given Sol-Gel Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Aditxt.
Profitability
This table compares Aditxt and Sol-Gel Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
| Sol-Gel Technologies | -910.14% | -44.05% | -36.96% |
Institutional & Insider Ownership
15.5% of Aditxt shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Sol-Gel Technologies beats Aditxt on 13 of the 15 factors compared between the two stocks.
About Aditxt
Aditxt, Inc. (NASDAQ: ADTX) is a biotechnology company focused on developing technologies designed to monitor and improve the human immune system. Its work centers on immune profiling, precision health and personalized medicine, with the goal of helping healthcare providers and researchers better understand individual immune responses. The company’s primary technology platform, AditxtScore, is designed to analyze multiple immune system biomarkers simultaneously. The platform is intended for applications including disease detection, monitoring immune responses to infections and vaccines, and supporting the development of personalized treatment strategies.
About Sol-Gel Technologies
Sol-Gel Technologies is an Israel-based dermatology company that develops topical treatments for skin conditions. Its proprietary technology uses silica-based microencapsulation to formulate active ingredients for topical use. The company’s products include Epsolay, a benzoyl peroxide cream approved in the United States for inflammatory lesions of rosacea, and Twyneo, a topical combination of tretinoin and benzoyl peroxide approved for acne vulgaris. Sol-Gel has pursued commercialization and licensing opportunities in the United States and other markets.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
